These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 31573749)

  • 1. Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy.
    Hsieh JC; Wang HM; Wu MH; Chang KP; Chang PH; Liao CT; Liau CT
    Head Neck; 2019 Oct; 41 Suppl 1():19-45. PubMed ID: 31573749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunocheckpoint inhibition in head and neck squamous cell carcinoma: the current status and progress].
    Huang LL; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):641-647. PubMed ID: 31550852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
    Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro humanized 3D microfluidic chip for testing personalized immunotherapeutics for head and neck cancer patients.
    Al-Samadi A; Poor B; Tuomainen K; Liu V; Hyytiäinen A; Suleymanova I; Mesimaki K; Wilkman T; Mäkitie A; Saavalainen P; Salo T
    Exp Cell Res; 2019 Oct; 383(2):111508. PubMed ID: 31356815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
    Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
    Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel prognostic clinical factors and biomarkers for outcome prediction in head and neck cancer: a systematic review.
    Budach V; Tinhofer I
    Lancet Oncol; 2019 Jun; 20(6):e313-e326. PubMed ID: 31162105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
    Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
    Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
    Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers for immunotherapy response in head and neck cancer.
    Gavrielatou N; Doumas S; Economopoulou P; Foukas PG; Psyrri A
    Cancer Treat Rev; 2020 Mar; 84():101977. PubMed ID: 32018128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developments and future prospects of personalized medicine in head and neck squamous cell carcinoma diagnoses and treatments.
    Jayawickrama SM; Ranaweera PM; Pradeep RGGR; Jayasinghe YA; Senevirathna K; Hilmi AJ; Rajapakse RMG; Kanmodi KK; Jayasinghe RD
    Cancer Rep (Hoboken); 2024 Mar; 7(3):e2045. PubMed ID: 38522008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of tumor DNA as a diagnostic tool for head and neck squamous cell carcinoma.
    Chan JYK; Zhen G; Agrawal N
    Semin Cancer Biol; 2019 Apr; 55():1-7. PubMed ID: 30082187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapeutic Approaches to Head and Neck Cancer.
    Nasser H; St John M
    Crit Rev Oncog; 2018; 23(3-4):161-171. PubMed ID: 30311572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: A systematic review and meta-analysis.
    Galvis MM; Borges GA; Oliveira TB; Toledo IP; Castilho RM; Guerra ENS; Kowalski LP; Squarize CH
    Crit Rev Oncol Hematol; 2020 Jun; 150():102966. PubMed ID: 32371338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain metastasis from squamous cell carcinoma of the head and neck: a review of the literature in the genomic era.
    Barrett TF; Gill CM; Miles BA; Iloreta AMC; Bakst RL; Fowkes M; Brastianos PK; Bederson JB; Shrivastava RK
    Neurosurg Focus; 2018 Jun; 44(6):E11. PubMed ID: 29852772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives.
    Jiménez-Labaig P; Rullan A; Braña I; Hernando-Calvo A; Moreno V; Doger B; Bitar G; Ap Dafydd D; Melcher A; Harrington KJ
    Cancer Treat Rev; 2024 Jun; 127():102746. PubMed ID: 38696902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
    Solomon B; Young RJ; Rischin D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):228-240. PubMed ID: 29355614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for Head and Neck Cancer.
    Sim F; Leidner R; Bell RB
    Hematol Oncol Clin North Am; 2019 Apr; 33(2):301-321. PubMed ID: 30833002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research Progress in Head and Neck Squamous Cell Carcinoma: Best Abstracts of ICHNO 2015.
    Economopoulou P; Bourhis J; Psyrri A
    Am Soc Clin Oncol Educ Book; 2015; ():e323-8. PubMed ID: 25993192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.